(Q34623334)

3 August 2017

1 reference

title

Development of vaccines against meningococcal disease (English)

1 reference

3 August 2017

Luis Jódar

1

1 reference

3 August 2017

Ian M Feavers

series ordinal

2

1 reference

3 August 2017

David Salisbury

series ordinal

3

1 reference

3 August 2017

Dan M Granoff

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

359

1 reference

3 August 2017

issue

9316

1 reference

3 August 2017

page(s)

1499-1508

1 reference

Mortality in Meningococcal Infections

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Mortality in meningococcal disease in Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Case fatality of meningococcal disease in western Norway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Decline of Childhood Haemophilus influenzae Type b (Hib) Disease in the Hib Vaccine Era

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

New perspectives on bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Paediatric, invasive pneumococcal disease in Switzerland, 1985-1994. Swiss Pneumococcal Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Mortality from meningococcal disease during an epidemic in The Gambia, West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Sequelae of epidemic meningococcal meningitis in Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Complications and sequelae of meningococcalinfections in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Meningitis outbreaks and vaccination strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

[Introduction of a conjugate vaccine against Hib in Chile and Uruguay]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Efficacy of pneumococcal conjugate vaccines in large scale field trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Update on Haemophilus influenzae serotype b and meningococcal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Recent changes in meningococcal disease in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Invasive meningococcal disease in adolescents and young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Risk factors for meningococcal disease in college students

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Risk of meningococcal infection in college students.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Group A meningococcal disease in skid rows: epidemiology and implications for control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Smoking, the environment and meningococcal disease: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Possible association of mycoplasma and viral respiratory infections with bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Influenza A and meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Prevalence of deficits of complement components in patients with recurrent meningococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Letter: Recognition of diphtheria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Manson Lecture. Meningococcal meningitis in Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Serogroup W135 meningococcal disease in Hajj pilgrims.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Shift in the age-distribution of meningococcal disease as predictor of an epidemic?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Meningococcal serotypes and serogroup B disease in north-west Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Neisseria meningitidis Infections in Northern Norway: An Epidemic in 1974-1975 Due Mainly to Group B Organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Epidemiology of meningococcal meningitis in Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Serotypes and polyacrylamide gel electrophoresis types among disease-associated isolates of group B Neisseria meningitidis in Spain, 1976-1979.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

An Epidemic of Disease Due to Serogroup B Neisseria meningitidis in Alabama: Report of an Investigation and Community-Wide Prophylaxis with a Sulfonamide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Group B meningococcal infection in children during an epidemic in Cape Town, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Genetic characterization of a new variant within the ET-37 complex of Neisseria meningitidis associated with outbreaks in various parts of the world

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Molecular epidemiology of sporadic (endemic) serogroup C meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Outbreak of meningococcal disease in western Norway due to a new serogroup C variant of the ET-5 clone: effect of vaccination and selective carriage eradication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Prevention of Meningococcal Disease by Group C Polysaccharide Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Control of meningococcal infection in the African meningitis belt by selective vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Control of epidemic meningococcal meningitis by mass vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Epidemic of meningococcal meningitis in Bamako, Mali: epidemiological features and analysis of vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Meningococcal carriage, meningococcal disease and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Kinetics of Antibody Production to Group A and Group C Meningococcal Polysaccharide Vaccines Administered during the First Six Years of Life: Prospects for Routine Immunization of Infants and Children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Meningococcal vaccine in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Epidemiology and prevention of meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Immune Response of Human Infants to Polysaccharide Vaccines of Groups A and C Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Antibody Responses of Human Infants to Three Doses of Group A Neisseria meningitidis Polysaccharide Vaccine Administered at Two, Four, and Six Months of Age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Control of meningococcal disease in west Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Capsule switching of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Meningococcal conjugate vaccines: new opportunities and new challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Rapid serogroup switching in Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Sequencing of porA from clinical isolates of Neisseria meningitidis defines a subtyping scheme and its genetic regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Detection of antibodies to common antigens of pathogenic and commensal Neisseria species

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Neisseria lactamica and Neisseria meningitidis share lipooligosaccharide epitopes but lack common capsular and class 1, 2, and 3 protein epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Reverse vaccinology, a genome-based approach to vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

In vivo genetic analysis of bacterial virulence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Functional genomics of Neisseria meningitidis pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

Antibacterial vaccine design using genomics and proteomics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908416-7

7 January 2021

10.1016/S0140-6736(02)08416-7

Identifiers

DOI

1 reference

3 August 2017

1 reference